SOURCE: Quture International, Inc.
DAYTONA BEACH, FL--(Marketwired - Oct 3, 2013) - Quture International, Inc. (OTCQB: QUTR) today announced an agreement with Therapeutic Solutions International, Inc. (OTCQB: TSOI), Oceanside, CA (TSI), to implement QualOptima analytics software as a service (SaaS) for TSI, through its newly formed consulting subsidiary QualVal Solutions, LLC. TSI markets and sells dental appliances that treat intractable migraine headache pain with extraordinary clinical results in the international market. As TSI enters new markets in South America and Asia, and continues its marketing efforts throughout Europe and the Pacific Rim, Quture will use the QualOptima Analytics System to revolutionize marketing of these devices. Specific clinical metrics and algorithms embedded in the QualOptima software, will analyze available databases using targeted personalized risk factors. This data will identify optimal candidates for treatment with TSI's Migran-X device by their neurologists and dentists. Quture's remarkable intellectual property (IP) will then be applied to measure performance and outcomes of TSI's Migran-X® devices in patients to continuously monitor patient experience and clinical effectiveness. As TSI and Quture target country-specific markets, they intend to calculate financial projections for new revenue streams to TSI and Quture.
As TSI potentially expands into other medical device manufacturing and distribution, extensive databases available to Quture will be mined, again for marketing and outcomes measurement, as well as to potentially monitor patient experience and clinical effectiveness.
"We are excited about this opportunity, working with Quture, to increase our sales through more targeted marketing efforts and to better monitor and analyze clinical outcomes," said Tim Dixon, Chairman & CEO of TSI. "Therapeutic Solutions markets an extraordinary FDA cleared (510(k)) dental appliance approved for the prevention of medically diagnosed migraine pain. Both companies enjoy unique differentiation in their respective markets. We anticipate that the collaboration of our companies will increase our revenues and positions in our respective marketplaces."
Clinical analytics for TSI's Migran-X device will provide Quture with its first application of QualOptima to medical device manufacturers. The application of Quture's technology adds a new major health care market segment -- medical device manufacturing and distribution, to Quture's business. TSI will collaborate with Quture for continued development and testing of its FPPE-OPPE (Focused and Ongoing Professional Practice Evaluation) compliance application for proctoring physicians, dentists and other clinicians for new clinical procedures and associated medical devices.
"The vision of Quture continues to be manifested in new market segments for potential customers in medical devices," said Landon Feazell, Chairman & CEO of Quture. "We look forward to proving the value proposition of QualOptima for medical devices, not only hospitals and physicians. Quture is pleased to announce this agreement with Therapeutic Solutions as the first contract of its subsidiary QualVal Solutions providing consulting services bundled with our QualOptima product."
ABOUT QUTURE INTERNATIONAL, INC. (www.quture.com)
Quture International, Inc. (QUTR) is the proven and experienced clinical performance and outcomes analytics company in the United States. The vision of Quture is to connect all constituents in the global health and health care community to clinically and financially focused and sound data transformed through analytics to knowledge that empowers data-driven decisions for results-driven success. As an Application Partner of InterSystems Corporation, Quture's technology for capturing, integrating and aggregating data on the InterSystems Enterprise platform is unequalled. The Company's unique product QualOptima develops a second generation CLINICAL database implementing Quture's core competence of clinical content with evidence-based metrics developed for more than 35 years. QualOptima empowers clinical performance enhancement to achieve optimal patient outcomes. Quture's brand is centered on the value proposition of trust, transparency and independence. As the free enterprise solution to improving health and healthcare while reducing costs, Quture is positioned to become the leading clinical knowledge company in the world. Quture International is a Nevada corporation trading under the symbol QUTR.
ABOUT THERAPEUTIC SOLUTIONS, INC. (www.therapeuticsolutionsint.com)
Therapeutic Solutions International is a global manufacturer of the chairside anterior midpoint stop appliance (AMPSA) devices marketed internationally under the trade names Migran-X® and AMPSA CS®, which have helped countless patients prevent debilitating migraine and tension headache pain, bruxism, clenching, grinding, and TMJ disorders. The Migran-X® and AMPSA CS® devices are the most effective non-drug US FDA cleared dental method of migraine prevention on the market today. Non-US dentists and physicians can order our AMPSA products at www.ordertsoi.com.
This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.